ADC Therapeutics (ADCT) Free Cash Flow (2020 - 2026)
ADC Therapeutics (ADCT) posted Free Cash Flow of -$29.7 million for Q1 2026, up 4.44% sequentially from -$31.1 million in Q4 2025, and up 47.45% YoY from -$20.2 million in Q1 2025.
ADC Therapeutics (ADCT) Free Cash Flow (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$29.7 million in Q1 2026.
- Quarterly Free Cash Flow rose 47.45% year-over-year to -$29.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.6 million (up 16.16% YoY) and the FY2025 annual result came in at -$141.4 million, down 13.42% from the prior year.
- Free Cash Flow grew to -$29.7 million in Q1 2026 per ADCT's latest filing, from -$31.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $2.0 million in Q3 2022 and troughed at -$56.6 million in Q1 2025.
- A 5-year average of -$32.8 million and a median of -$32.0 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 103.34% in 2022, then tumbled 1965.77% in 2023.
- Over 5 years, Free Cash Flow stood at -$53.8 million in 2022, then soared by 40.63% to -$32.0 million in 2023, then surged by 31.35% to -$21.9 million in 2024, then tumbled by 41.84% to -$31.1 million in 2025, then increased by 4.44% to -$29.7 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$29.7 million, -$31.1 million, and -$29.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | -11.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.81 Mn |
| Jun 30, 2026 | -11.81 Mn |
| Mar 31, 2026 | -29.74 Mn |
| Mar 31, 2026 | -29.74 Mn |
| Dec 31, 2025 | -31.12 Mn |
| Dec 31, 2025 | -31.12 Mn |
| Sep 30, 2025 | -29.63 Mn |
| Sep 30, 2025 | -29.63 Mn |
| Jun 30, 2025 | -24.09 Mn |
| Jun 30, 2025 | -24.09 Mn |
| Mar 31, 2025 | -56.60 Mn |
| Mar 31, 2025 | -56.60 Mn |
| Dec 31, 2024 | -21.94 Mn |
| Dec 31, 2024 | -21.94 Mn |
| Sep 30, 2024 | -25.26 Mn |
| Sep 30, 2024 | -25.26 Mn |
| Jun 30, 2024 | -32.88 Mn |
| Jun 30, 2024 | -32.88 Mn |
| Mar 31, 2024 | -44.63 Mn |
| Mar 31, 2024 | -44.63 Mn |